Pharma IT
Wo Datenintegrität, Automatisierung und KI sich tatsächlich mit der Produktionsebene verbinden.
ArtikelAI Governance In Pharma: Is It Becoming The New GMP?
GMP built trust in physical manufacturing. Now algorithms need the same guardrails, here's why AI governance is following its playbook.
Rethinking Life Sciences Quality & Manufacturing Operations in the Age of AI & Connected Systems
Discover how AI and connected systems enable real-time quality management in modern life sciences manufacturing.
Safety Data Was Never a Cost. AI Just Proved It.
AI in Pharmacovigilance is unlocking value long buried in safety data, from drug repurposing to faster regulatory submissions.
Building the Knowledge Foundations for AI-Ready Pharmaceutical Quality Systems
How pharmaceutical quality systems can build the knowledge foundations needed for trustworthy AI across CMC and CGMP.
5 Considerations for Building a More Connected Digital QA/QC Laboratory
Explore five key considerations for building a connected digital QA/QC laboratory, with practical insights on data integrity, integration, standardization, and AI readiness.
Audit Trail Review In Pharma Is The New FDA Finding, Not Existence
FDA inspectors now ask who reviewed the audit trail, not just whether one exists, here's what's driving Audit Trail Review In Pharma citations.
Annex 22 Is Not Law Yet. What to Invest in Now
Annex 22 isn't law yet — this piece verifies its real EudraLex status and lays out the 7 investments pharma sites should fund now, regardless of the final date.
Rasayan Labs Emerges as a Unified AI Operating System for Generic Drug Development, Moving Beyond the Limits of Traditional Tools
Discover how Rasayan Labs is unifying AI-powered generic drug development with a single platform that accelerates API R&D, formulation, regulatory workflows, and more.
20260804110923.webp&w=1920&q=75&dpl=dpl_Fe2VLXz7WmA2eVjpEbUc2scjDNEB)
Can AI Decode the Gut? : Machine Learning in Microbiome Research
AI is decoding microbial patterns humans can't see. Here's how machine learning is transforming microbiome research into clinical reality.
How ML Virtual Screening Is Scaling Cancer Drug Targets?
ML virtual screening hits 18-45% in prospective trials vs sub-1% for HTS, unlocking undruggable cancer targets.